Pharmaceutical Executive-01-01-2015

Examining a new three-part formula to enable the supply chain function to manage market pressures while delivering on the bottom line.

In a follow-up to our November CEO profile, Novo Nordisk’s Jesper Høiland writes how pharma companies and insurers are learning to collaborate.

Brand success can hinge on discovering the deeper motivations of customers and addressing the cognitive biases that result.

I offered up a prediction: that the future of the biopharmaceutical business depended on how managers fared on five key measures of performance.

Pharm Exec’s annual report highlights the key scientific, commercial, and reputational trends shaping the industry in the year ahead.

The Canadian R&D industry, which boasts a rich history of drug innovation, celebrates a series of anniversaries.

Pharm Exec profiles Sanofi EVP Pascale Witz, tagged with the assignment to move a lumbering biopharma giant closer to the embrace of the patient perspective in healthcare.

With spending on healthcare increasing in Malaysia, access to innovative drugs remains a challenge as the country juggles its dual public-private health system.